- Home
- GLPG vs SRPT Comparison
GLPG vs SRPT Comparison
Compare GLPG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SRPT
- Stock Information
- Founded
- GLPG 1999
- SRPT 1980
- Country
- GLPG Belgium
- SRPT United States
- Employees
- GLPG N/A
- SRPT N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- GLPG Health Care
- SRPT Health Care
- Exchange
- GLPG Nasdaq
- SRPT Nasdaq
- Market Cap
- GLPG 2.0B
- SRPT 1.7B
- IPO Year
- GLPG 2005
- SRPT 1997
- Fundamental
- Price
- GLPG $33.01
- SRPT $16.75
- Analyst Decision
- GLPG Sell
- SRPT Hold
- Analyst Count
- GLPG 4
- SRPT 29
- Target Price
- GLPG $25.33
- SRPT $46.46
- AVG Volume (30 Days)
- GLPG 372.1K
- SRPT 19.6M
- Earning Date
- GLPG 07-23-2025
- SRPT 08-11-2025
- Dividend Yield
- GLPG N/A
- SRPT N/A
- EPS Growth
- GLPG N/A
- SRPT N/A
- EPS
- GLPG N/A
- SRPT N/A
- Revenue
- GLPG $323,674,692.00
- SRPT $2,233,371,000.00
- Revenue This Year
- GLPG $0.78
- SRPT $3.52
- Revenue Next Year
- GLPG N/A
- SRPT N/A
- P/E Ratio
- GLPG N/A
- SRPT N/A
- Revenue Growth
- GLPG 5.43
- SRPT 59.15
- 52 Week Low
- GLPG $22.36
- SRPT $10.42
- 52 Week High
- GLPG $33.86
- SRPT $146.38
- Technical
- Relative Strength Index (RSI)
- GLPG 67.37
- SRPT 44.29
- Support Level
- GLPG $31.98
- SRPT $10.42
- Resistance Level
- GLPG $33.66
- SRPT $14.54
- Average True Range (ATR)
- GLPG 0.85
- SRPT 2.15
- MACD
- GLPG 0.17
- SRPT 0.66
- Stochastic Oscillator
- GLPG 88.39
- SRPT 50.88
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.